Identification of novel DNA methylation inhibitors via a two-component reporter gene system

Persistent Link:
http://hdl.handle.net/10150/610175
Title:
Identification of novel DNA methylation inhibitors via a two-component reporter gene system
Author:
Lin, Yi-Shiuan; Shaw, Arthur; Wang, Shi-Gang; Hsu, Chia-Chen; Teng, I-W; Tseng, Min-Jen; Huang, Tim; Chen, Ching-Shih; Leu, Yu-Wei; Hsiao, Shu-Huei
Affiliation:
Human Epigenomics Center, Department of Life Science, Institute of Molecular Biology and Institute of Biomedical Science, National Chung Cheng University, Chia-Yi, 621, Taiwan; Department of Pharmacology and Toxicology, College of Pharmacy, Southwest Comprehensive Center for Drug Discovery and Development, University of Arizona, Tucson, AZ 85721, USA; Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
Issue Date:
2011
Publisher:
BioMed Central
Citation:
Lin et al. Journal of Biomedical Science 2011, 18:3 http://www.jbiomedsci.com/content/18/1/3
Journal:
Journal of Biomedical Science
Rights:
© 2011 Lin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)
Collection Information:
This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.
Abstract:
BACKGROUND:Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2'-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2'-deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop potent DNA methylation inhibitors through lead optimization.METHODS:We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing procainamide derivatives.RESULTS:A lead agent IM25, which exhibits substantially higher potency in GSTp1 DNA demethylation with lower cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2'-deoxycytidine, was identified by the screening platform.CONCLUSIONS:Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is currently under investigation.
EISSN:
1423-0127
DOI:
10.1186/1423-0127-18-3
Version:
Final published version
Additional Links:
http://www.jbiomedsci.com/content/18/1/3

Full metadata record

DC FieldValue Language
dc.contributor.authorLin, Yi-Shiuanen
dc.contributor.authorShaw, Arthuren
dc.contributor.authorWang, Shi-Gangen
dc.contributor.authorHsu, Chia-Chenen
dc.contributor.authorTeng, I-Wen
dc.contributor.authorTseng, Min-Jenen
dc.contributor.authorHuang, Timen
dc.contributor.authorChen, Ching-Shihen
dc.contributor.authorLeu, Yu-Weien
dc.contributor.authorHsiao, Shu-Hueien
dc.date.accessioned2016-05-20T09:00:20Z-
dc.date.available2016-05-20T09:00:20Z-
dc.date.issued2011en
dc.identifier.citationLin et al. Journal of Biomedical Science 2011, 18:3 http://www.jbiomedsci.com/content/18/1/3en
dc.identifier.doi10.1186/1423-0127-18-3en
dc.identifier.urihttp://hdl.handle.net/10150/610175-
dc.description.abstractBACKGROUND:Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2'-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2'-deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop potent DNA methylation inhibitors through lead optimization.METHODS:We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing procainamide derivatives.RESULTS:A lead agent IM25, which exhibits substantially higher potency in GSTp1 DNA demethylation with lower cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2'-deoxycytidine, was identified by the screening platform.CONCLUSIONS:Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is currently under investigation.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.jbiomedsci.com/content/18/1/3en
dc.rights© 2011 Lin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)en
dc.titleIdentification of novel DNA methylation inhibitors via a two-component reporter gene systemen
dc.typeArticleen
dc.identifier.eissn1423-0127en
dc.contributor.departmentHuman Epigenomics Center, Department of Life Science, Institute of Molecular Biology and Institute of Biomedical Science, National Chung Cheng University, Chia-Yi, 621, Taiwanen
dc.contributor.departmentDepartment of Pharmacology and Toxicology, College of Pharmacy, Southwest Comprehensive Center for Drug Discovery and Development, University of Arizona, Tucson, AZ 85721, USAen
dc.contributor.departmentHuman Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USAen
dc.contributor.departmentDivision of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USAen
dc.identifier.journalJournal of Biomedical Scienceen
dc.description.collectioninformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.